Wiser Gene Annotations with 5' SAGE?

THE KEYS TO CAGE© 2003 National Academy of Sciencesand its competitors are a 5' cap-trapping step and a class II restriction enzyme (MmeI), which cleaves DNA 20/18 bp downstream of the recognition site to create the sequence tag. (Reprinted from T. Shiraki, Proc Nat Acad Sci, 100:15776–81, 2003.)Serial analysis of gene expression (SAGE) has been used extensively to map and quantify transcripts in different tissues. But the technique, which extracts short oligos (14–21 bp long) f

Written byCathy Holding
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

© 2003 National Academy of Sciences

and its competitors are a 5' cap-trapping step and a class II restriction enzyme (MmeI), which cleaves DNA 20/18 bp downstream of the recognition site to create the sequence tag. (Reprinted from T. Shiraki, Proc Nat Acad Sci, 100:15776–81, 2003.)

Serial analysis of gene expression (SAGE) has been used extensively to map and quantify transcripts in different tissues. But the technique, which extracts short oligos (14–21 bp long) from the 3' ends of pooled mRNAs, offers no insight into transcription start points. Three recent papers describe SAGE variants that can.

First, Piero Carninci's group at the RIKEN Genomic Sciences Center in Japan described a "cap analysis gene expression" (CAGE) method that uses "cap-trapping" to isolate an mRNA's 5' end.1 Next, a team at the Genome Institute of Singapore used 5' and 3' "LongSAGE" approaches to separately map both ends of a transcript.2 Finally, Kouji ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies